Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ASLN |
---|---|---|
09:32 ET | 1166 | 0.45 |
09:36 ET | 300 | 0.4581 |
09:48 ET | 2500 | 0.458 |
10:03 ET | 10768 | 0.45 |
10:15 ET | 1350 | 0.4501 |
10:17 ET | 350 | 0.4503 |
10:21 ET | 100 | 0.4503 |
10:37 ET | 28488 | 0.4301 |
10:39 ET | 100 | 0.4301 |
10:48 ET | 100 | 0.4579 |
10:50 ET | 200 | 0.45 |
10:51 ET | 1398 | 0.44 |
10:53 ET | 400 | 0.4412 |
11:00 ET | 312 | 0.44 |
11:18 ET | 4485 | 0.4303 |
11:20 ET | 400 | 0.4303 |
11:22 ET | 100 | 0.4303 |
11:42 ET | 230 | 0.44 |
11:44 ET | 110 | 0.458 |
11:51 ET | 300 | 0.449 |
12:03 ET | 300 | 0.456 |
12:18 ET | 500 | 0.44 |
12:23 ET | 24988 | 0.456 |
12:25 ET | 500 | 0.455999 |
12:36 ET | 1100 | 0.44 |
12:38 ET | 500 | 0.4539 |
12:39 ET | 100 | 0.44 |
12:50 ET | 100 | 0.44 |
12:54 ET | 900 | 0.447 |
12:56 ET | 100 | 0.44 |
01:03 ET | 100 | 0.44 |
01:06 ET | 2000 | 0.4428 |
01:08 ET | 500 | 0.44 |
01:12 ET | 100 | 0.44 |
01:26 ET | 150 | 0.4411 |
01:33 ET | 700 | 0.44 |
01:42 ET | 100 | 0.44 |
02:02 ET | 200 | 0.44 |
02:33 ET | 100 | 0.44 |
02:36 ET | 100 | 0.44 |
02:40 ET | 100 | 0.44 |
02:44 ET | 600 | 0.447 |
02:45 ET | 100 | 0.44 |
03:14 ET | 1993 | 0.445 |
03:16 ET | 400 | 0.448 |
03:18 ET | 800 | 0.44 |
03:20 ET | 100 | 0.445 |
03:21 ET | 1800 | 0.44 |
03:23 ET | 100 | 0.44 |
03:25 ET | 1400 | 0.4519 |
03:27 ET | 200 | 0.44 |
03:30 ET | 100 | 0.44 |
03:32 ET | 100 | 0.44 |
03:36 ET | 100 | 0.44 |
03:39 ET | 100 | 0.44 |
03:56 ET | 621 | 0.4474 |
03:57 ET | 699 | 0.44 |
03:59 ET | 172 | 0.447 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Aslan Pharmaceuticals Ltd | 31.2M | -1.0x | --- |
Spruce Biosciences Inc | 31.7M | -0.7x | --- |
OncoSec Medical Inc | 30.3M | -0.7x | --- |
Oncorus Inc | 32.1M | -0.5x | --- |
Bioxytran Inc | 32.2M | -7.5x | --- |
NeuBase Therapeutics Inc | 32.3M | -1.0x | --- |
ASLAN Pharmaceuticals Limited (ASLAN) is a clinical-stage immunology focused biopharmaceutical company. The Company is engaged in developing treatments to transform the lives of patients. The Company is focused developing ASLAN004, an antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, an oral inhibitor of dihydroorotate dehydrogenase (DHODH), which is being developed for autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore, and conducts clinical development programs globally.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $31.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 13.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.41 |
EPS | $-0.44 |
Book Value | $-0.25 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.